Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER3 | P43115 | 17/20 | 0.66 |
| ▸ | PTGER4 | P35408 | 4/20 | 0.54 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.54 |
| ▸ | PTGFR | P43088 | 1/20 | 0.54 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.54 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.54 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1137334 | 1.00 | PTGER3 (0.66) | PTGER3PTGER4TBXA2RPTGFRPTGER2 | |
| SCHEMBL2890763 | 0.87 | PTGER3 (0.65) | PTGER3PTGER4CTRB1 | |
| SCHEMBL2890761 | 0.87 | PTGER3 (0.65) | PTGER3PTGER4CTRB1 | |
| SCHEMBL2890111 | 0.84 | PTGER3 (0.58) | PTGER3 | |
| SCHEMBL2890109 | 0.84 | PTGER3 (0.58) | PTGER3 | |
| SCHEMBL1137707 | 0.79 | PTGER3 (0.66) | PTGER3PTGER4TBXA2RPTGFRPTGER2 | |
| SCHEMBL1137702 | 0.79 | PTGER3 (0.66) | PTGER3PTGER4TBXA2RPTGFRPTGER2 | |
| SCHEMBL13354405 | 0.78 | PTGER3 (0.51) | PTGER3PTGER4TBXA2RPTGFRPTGER2 | |
| SCHEMBL1137784 | 0.77 | PTGER3 (0.57) | PTGER3PTGER4TBXA2RPTGFRPTGER2 | |
| SCHEMBL4220781 | 0.77 | PTGER3 (0.57) | PTGER3PTGER4TBXA2RPTGFRPTGER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1812388-B1 | SULFONAMIDE PERI-SUBSTITUTED BICYCLICS FOR OCCLUSIVE ARTERY DISEASE | DECODE GENETICS EHF (IS) | 2011-02-23 | — | — | EP | disclosed |
| US-20090291948-A1 | SULFONAMIDE PERI-SUBSTITUTED BICYCLICS FOR OCCLUSIVE ARTERY DISEASE | DECODE GENETICS EHF (IS) | 2009-11-26 | — | — | US | disclosed |
| US-7598397-B2 | Sulfonamide peri-substituted bicyclics for occlusive artery disease | DECODE GENETICS EHF (IS) | 2009-10-06 | — | — | US | disclosed |
| US-20060079520-A1 | Sulfonamide peri-substituted bicyclics for occlusive artery disease | SAGA INVESTMENTS LLC | 2006-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079520-A1 | Sulfonamide peri-substituted bicyclics for occlusive artery disease | PTGIS, PTGIR, PTGS2 | PTGER3 19/4885PTGER4 21/4885TBXA2R 8/4885 |
| US-20090291948-A1 | SULFONAMIDE PERI-SUBSTITUTED BICYCLICS FOR OCCLUSIVE ARTERY DISEASE | PTGIS, PTGIR, PTGS2 | PTGER3 19/4885PTGER4 21/4885TBXA2R 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.